Cogstate (ASX:CGS) - Aandelenkoers, Nieuws & Analyse

CGS Overzicht aandelen

Cogstate Limited, een neurowetenschappelijk technologiebedrijf, houdt zich bezig met het creëren, valideren en op de markt brengen van digitale hersengezondheidsevaluaties die worden gebruikt in zowel academisch als door de industrie gesponsord onderzoek. Meer informatie

CGS fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	2/6
Prestaties in het verleden	5/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 75.6% onder onze schatting van de reële waarde

De winst zal naar verwachting met 6.63% per jaar groeien

De winst groeide het afgelopen jaar met 52.8%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

CGS onze risicocontroles hebben doorstaan.

Cogstate Limited Concurrenten

SDI

ASX:SDI

AU$127.8m

Pacific Smiles Group

ASX:PSQ

AU$312.0m

SILK Laser Australia

ASX:SLA

AU$177.4m

Austco Healthcare

ASX:AHC

AU$91.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Cogstate
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.99
52 Week Hoogtepunt	AU$1.56
52 Week Laag	AU$0.80
Bèta	0.091
11 maand verandering	8.79%
3 maanden verandering	-14.66%
1 Jaar Verandering	-32.19%
33 jaar verandering	-57.33%
5 jaar verandering	147.50%
Verandering sinds IPO	98.00%

Recent nieuws en updates

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Aug 30

Recent updates

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Aug 30

There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital

Jul 26

Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%

Mar 23

Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts

Mar 02

Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate

Jan 13

Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%

Oct 04

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Sep 28

Returns On Capital Are A Standout For Cogstate (ASX:CGS)

Sep 02

We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease

Jun 30

Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital

Mar 22

We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation

Oct 20

Cogstate (ASX:CGS) Is Looking To Continue Growing Its Returns On Capital

Jul 23

Is Cogstate (ASX:CGS) Using Too Much Debt?

Apr 29

What Can The Trends At Cogstate (ASX:CGS) Tell Us About Their Returns?

Mar 14

Here's What Cogstate Limited's (ASX:CGS) Shareholder Ownership Structure Looks Like

Feb 21

How Much Is Cogstate's (ASX:CGS) CEO Getting Paid?

Jan 17

Can You Imagine How Jubilant Cogstate's (ASX:CGS) Shareholders Feel About Its 214% Share Price Gain?

Dec 05

Rendement voor aandeelhouders

	CGS	AU Healthcare Services	AU Markt
7D	2.6%	2.7%	-0.07%
1Y	-32.2%	121.0%	16.9%

Rendement versus industrie: CGS presteerde slechter dan de Australian Healthcare Services -sector, die het afgelopen jaar een rendement van 121 % opleverde.

Rendement versus markt: CGS presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 16.9 % opleverde.

Prijsvolatiliteit

Is CGS's price volatile compared to industry and market?
CGS volatility
CGS Average Weekly Movement	7.7%
Healthcare Services Industry Average Movement	8.2%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.4%

Stabiele aandelenkoers: CGS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van CGS is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	160	Brad O'Connor	www.cogstate.com

Cogstate Limited, een neurowetenschappelijk technologiebedrijf, houdt zich bezig met het creëren, valideren en op de markt brengen van digitale hersengezondheidsbeoordelingen die worden gebruikt in zowel academisch als door de industrie gesponsord onderzoek. De cognitieve diensten van het bedrijf omvatten projectmanagement, datamanagement, wetenschappelijk advies, statistische analyse, schaleninkoop, ratertraining en monitoringoplossingen. Het bedrijf is betrokken bij het ontwerp en de levering van kwaliteitsborgingsdiensten in klinische onderzoeken, gericht op het toedienen, scoren en registreren van conventionele hersengezondheidstests.

Cogstate Limited Samenvatting

Hoe verhouden de winst en inkomsten van Cogstate zich tot de beurswaarde?
CGS fundamentele statistieken
Marktkapitalisatie	AU$170.92m
Inkomsten(TTM)	AU$8.44m
Inkomsten(TTM)	AU$67.27m

20.2x

Koers/Winstverhouding

2.5x

P/S-verhouding

Is CGS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CGS resultatenrekening (TTM)
Inkomsten	US$43.43m
Kosten van inkomsten	US$19.13m
Brutowinst	US$24.30m
Overige uitgaven	US$18.85m
Inkomsten	US$5.45m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.032
Brutomarge	55.96%
Nettowinstmarge	12.55%
Schuld/Eigen Vermogen Verhouding	0.3%

Hoe presteerde CGS op de lange termijn?

Bekijk historische prestaties en vergelijking

CGS Overzicht aandelen

Beloningen

Risicoanalyse

Cogstate Limited Concurrenten

ASX:SDI

AU$127.8m

ASX:PSQ

AU$312.0m

ASX:SLA

AU$177.4m

ASX:AHC

AU$91.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Cogstate Appoints Kaycee Sink as Chief Medical Officer

CEO, MD & Executive Director exercised options to buy AU$965k worth of stock.

New minor risk - Market cap size

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Non-Executive Chairman recently bought AU$108k worth of stock

Full year 2024 earnings: EPS exceeds analyst expectations

Recent updates

Cogstate Appoints Kaycee Sink as Chief Medical Officer

CEO, MD & Executive Director exercised options to buy AU$965k worth of stock.

New minor risk - Market cap size

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Non-Executive Chairman recently bought AU$108k worth of stock

Full year 2024 earnings: EPS exceeds analyst expectations

Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025

Consensus revenue estimates decrease by 10%, EPS upgraded

There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital

If EPS Growth Is Important To You, Cogstate (ASX:CGS) Presents An Opportunity

First half 2024 earnings released: EPS: US$0.012 (vs US$0 in 1H 2023)

Price target decreased by 8.1% to AU$1.70

Investor sentiment deteriorates as stock falls 17%

The Price Is Right For Cogstate Limited (ASX:CGS)

Cogstate Limited to Report First Half, 2024 Results on Feb 22, 2024

Price target increased by 8.6% to AU$1.85

Cogstate Limited Provides Revenue Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Is Cogstate Limited (ASX:CGS) Trading At A 29% Discount?

Now 21% undervalued

Price target decreased by 9.0% to AU$1.70

Now 23% undervalued

Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023

Consensus EPS estimates increase by 12%

Returns Are Gaining Momentum At Cogstate (ASX:CGS)

Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

Investor sentiment deteriorates as stock falls 16%

CEO, MD & Executive Director recently bought AU$100k worth of stock

Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts

First half 2023 earnings released: EPS: US$0 (vs US$0.024 in 1H 2022)

Consensus EPS estimates increase by 23%, revenue downgraded

Investor sentiment deteriorates as stock falls 25%

Now 24% undervalued

Cogstate Limited to Report Fiscal Year 2023 Results on Aug 17, 2023

Now 22% undervalued

Cogstate Limited Announces Resignation of David Dolby as Non-Executive Director

Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate

Price target decreased to AU$1.92

High number of new and inexperienced directors

Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Returns On Capital Are A Standout For Cogstate (ASX:CGS)

Price target decreased to AU$2.18

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$2.41

Cogstate Limited Provides Earnings Guidance for the Fiscal Year 2023

High number of new and inexperienced directors

Price target decreased to AU$2.43

Investor sentiment improved over the past week

High number of new and inexperienced directors

We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease

Cogstate Announces Formation of Scientific Advisory Board

Consensus EPS estimates fall by 82%

Investor sentiment improved over the past week

Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital

First half 2022 earnings: Revenues and EPS in line with analyst expectations